WASHINGTON TRUST Co Grows Position in AbbVie Inc. $ABBV

WASHINGTON TRUST Co boosted its holdings in AbbVie Inc. (NYSE:ABBV) by 9.2% during the third quarter, Holdings Channel.com reports. The firm owned 31,308 shares of the company’s stock after acquiring an additional 2,647 shares during the quarter. WASHINGTON TRUST Co’s holdings in AbbVie were worth $7,249,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of AbbVie by 0.3% in the third quarter. Vanguard Group Inc. now owns 177,747,261 shares of the company’s stock worth $41,155,601,000 after purchasing an additional 448,554 shares during the last quarter. Geode Capital Management LLC boosted its position in AbbVie by 2.4% in the second quarter. Geode Capital Management LLC now owns 39,178,351 shares of the company’s stock worth $7,240,169,000 after purchasing an additional 924,761 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in AbbVie by 6.0% during the second quarter. Charles Schwab Investment Management Inc. now owns 26,783,329 shares of the company’s stock valued at $4,970,848,000 after buying an additional 1,517,222 shares during the period. Norges Bank purchased a new stake in shares of AbbVie in the 2nd quarter worth $4,288,200,000. Finally, Raymond James Financial Inc. increased its position in AbbVie by 41.8% in the second quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock worth $1,733,222,000 after buying an additional 2,753,312 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors.

AbbVie Stock Performance

NYSE ABBV opened at $231.69 on Monday. The stock has a 50-day simple moving average of $224.34 and a two-hundred day simple moving average of $223.26. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The firm has a market capitalization of $409.66 billion, a P/E ratio of 98.17, a PEG ratio of 0.81 and a beta of 0.35.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The business had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. During the same period in the previous year, the firm posted $2.16 EPS. The business’s revenue for the quarter was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.0%. AbbVie’s payout ratio is currently 293.22%.

Insider Buying and Selling at AbbVie

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of the business’s stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president directly owned 38,137 shares in the company, valued at approximately $8,771,510. The trade was a 36.98% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 0.25% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on ABBV shares. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, January 21st. BMO Capital Markets restated an “outperform” rating and set a $258.00 price objective on shares of AbbVie in a research report on Thursday, January 15th. Wall Street Zen raised shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Royal Bank Of Canada initiated coverage on AbbVie in a report on Tuesday, February 24th. They set an “outperform” rating and a $260.00 price objective for the company. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a research report on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $253.15.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.